LGALS3 and COVID-19: Authors have indicated that receiving a Gal-3 antagonist by COVID-19 patients led to a significant reduction in the viral load with full disappearance of the symptoms in most of the studied subjects, which is managed by inhibiting SARS-CoV-2 entry into cells through the inhibition of Gal-3 [34].